Luis Paz‐Ares
- Oncology top 0.05%
- Lung Cancer Research Studies 235
- Cancer Immunotherapy and Biomarkers 167
- Colorectal Cancer Treatments and Studies 97
- Peptidase Inhibition and Analysis 60
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations 375
- Lung Cancer Diagnosis and Treatment 114
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics 73
- Molecular Biology top 0.5%
- Cancer therapeutics and mechanisms 78
- Otorhinolaryngology top 0.5%
- Co-authors
- Yi‐Long WuFred R. HirschGiorgio V. ScagliottiWalter J. CurranJames L. MulshineRegina KwonIrene FerrerRocio García‐Carbonero
- Journals
- Journal of Clinical Oncology (190 papers)Annals of Oncology (118 papers)Journal of Thoracic Oncology (84 papers)
- Partner nations
- SpainUnited StatesGermany
In The Last Decade
Luis Paz‐Ares
655 papers receiving 22.5k citations
Hit Papers
Peers
Comparison fields: 5 of 156
- Oncology 13.2k
- Pulmonary and Respiratory Medicine 11.4k
- Cancer Research 4.2k
- Molecular Biology 7.6k
- Otorhinolaryngology 471
Countries citing papers authored by Luis Paz‐Ares
This map shows the geographic impact of Luis Paz‐Ares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Paz‐Ares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Paz‐Ares more than expected).
Fields of papers citing papers by Luis Paz‐Ares
This network shows the impact of papers produced by Luis Paz‐Ares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Paz‐Ares. The network helps show where Luis Paz‐Ares may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Luis Paz‐Ares, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 19 | |
| 5 | 2023 | 9 | |
| 6 | 2023 | 8 | |
| 7 | 2023 | 5 | |
| 8 | 2023 | 3 | |
| 9 | 2021 | 29 | |
| 10 | 2021 | 5 | |
| 11 | 2021 | 15 | |
| 12 | 2020 | 31 | |
| 13 | First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy | 2019 | 1 |
| 14 | 2018 | 17 | |
| 15 | 2017 | 232 | |
| 16 | 2014 | 257 | |
| 17 | 2014 | 200 | |
| 18 | 2013 | 15 | |
| 19 | EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studybreakdown → | 2011 | 453 |
| 20 | 2005 | 134 |
About Luis Paz‐Ares
Luis Paz‐Ares is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 690 papers that have together received 23.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (375 papers), Lung Cancer Research Studies (235 papers), Cancer Immunotherapy and Biomarkers (167 papers), Lung Cancer Diagnosis and Treatment (114 papers), Colorectal Cancer Treatments and Studies (97 papers), Cancer therapeutics and mechanisms (78 papers), Cancer Genomics and Diagnostics (73 papers) and Peptidase Inhibition and Analysis (60 papers). The work is most often cited by research in Oncology (13.2k citations), Pulmonary and Respiratory Medicine (11.4k citations) and Cancer Research (4.2k citations). Luis Paz‐Ares has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include Yi‐Long Wu, Fred R. Hirsch, Giorgio V. Scagliotti, Walter J. Curran, James L. Mulshine, Regina Kwon, Irene Ferrer, Rocio García‐Carbonero, Sonia Molina‐Pinelo and Amancio Carnero. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Clinical & Translational Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.